Mogamulizumab 在蕈样肉芽肿及其他 T 细胞肿瘤患者中诱导的光敏反应
回顾性分析 7 例接受 Mogamulizumab 治疗的皮肤淋巴瘤患者,其中 4 例在联合窄带 UVB 治疗后出现光敏性皮炎,光试验显示作用光谱为 UVB(3 例)或 UVB 与 UVA(1 例),皮损以 CD8+ T 细胞为主的苔藓样浸润且 Foxp3+ 调节性 T 细胞较淋巴瘤皮损减少。
要点
- 7 例接受 Mogamulizumab 治疗的皮肤淋巴瘤患者中 4 例出现光敏性皮炎。
- 光试验作用光谱为 UVB(3 例)或 UVB 与 UVA(1 例)。
- 光敏皮损以 CD8+ T 细胞为主,Foxp3+ 调节性 T 细胞较淋巴瘤皮损减少。
核心结论
- Mogamulizumab 治疗期间观察到光敏反应发生率增加,皮损中调节性 T 细胞减少提示该反应可能由自身反应性细胞毒性 T 细胞诱导。
研究设计与样本
- 回顾性研究,纳入 7 例接受 Mogamulizumab 治疗的皮肤淋巴瘤患者,其中 4 例在联合窄带 UVB 治疗后出现光敏性皮炎。
主要发现
- 4 例出现光敏性皮炎的患者包括 2 例蕈样肉芽肿、1 例成人 T 细胞白血病/淋巴瘤和 1 例 EB 病毒相关 T 细胞淋巴增殖性疾病。
- 光试验显示作用光谱为 UVB 者 3 例,为 UVB 与 UVA 者 1 例。
- 光敏性皮损组织病理表现为苔藓样组织反应伴 CD8+ T 细胞优势浸润,与慢性光化性皮炎特征相似。
- 光敏性皮损中 Foxp3+ 调节性 T 细胞较淋巴瘤皮损减少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mogamulizumab (Mog) is a defucosylated, therapeutic monoclonal antibody, targeting CCR4 and was first approved in Japan for the treatment of adult T-cell leukaemia/lymphoma (ATLL), followed by cutaneous T-cell lymphoma and peripheral T-cell lymphoma. OBJECTIVE: To retrospectively investigate development of photosensitivity in patients with mycosis fungoides and other T-cell neoplasms after treatment with Mog. METHODS: We treated seven cutaneous lymphoma patients with Mog. Upon combination treatment with narrow-band UVB, we noticed that four patients developed photosensitivity dermatitis following Mog therapy, including two cases of mycosis fungoides, one case of adult T-cell leukaemia/lymphoma and one case of EB virus-associated T-cell lymphoproliferative disorder. Phototest was performed with UVA and UVB, and immunohistochemical staining for CD4, CD8 and Foxp3 was conducted in both photosensitivity and lymphoma lesions. RESULTS: Phototest revealed that the action spectrum of the photosensitivity was UVB in three cases and both UVB and UVA in one case. Histopathologically, the photosensitive lesions were characterized by a lichenoid tissue reaction with a CD8+ T cell-dominant infiltrate, sharing the feature with chronic actinic dermatitis, an autoreactive photodermatosis with a cytotoxic T-cell response. Foxp3+ regulatory T cells (Tregs) were decreased in the photosensitivity lesions compared with the lymphoma lesions. CONCLUSION: Increased incidence of photosensitivity reaction was observed during Mog treatment. Decreased number of Tregs in the lesional skin suggests that this reaction is possibly induced by autoreactive cytotoxic T cells.
引用
- Masuda Y, Tatsuno K, Kitano S, et al. Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms. J Eur Acad Dermatol Venereol. 2018. PMID: 29341283. doi:10.1111/jdv.14797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。